We then used this model to profile the therapeutic effects and anti-tumour immune responses of VSVΔ51+T-DM1 combination revealing remarkable efficacy, even following systemic delivery, associated with both HER2-specific and non-specific immune-responses. Here, ERBB2 is linked to neoplasm.